Circio Holding ASA
TA50
Company Profile
Business description
Circio Holding ASA is a clinical-stage biotechnology company focused on the development of circular RNA (circRNA)-based therapeutics. The company is advancing its proprietary circVec platform for gene therapy and RNA-based applications, including programs targeting cancer such as mutant KRAS. It is also engaged in the development of novel RNA technologies aimed at improving the stability and efficacy of therapeutic gene expression.
Contact
c/o Mesh Community AS
Tordenskiolds Gate 2
Oslo0160
NORT: +47 92951788
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.40 | 35.80 | 0.40% |
| CAC 40 | 8,258.26 | 142.51 | 1.76% |
| DAX 40 | 25,389.10 | 500.54 | 2.01% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 65,158.19 | 1,819.12 | 2.87% |
| NZX 50 Index | 12,970.28 | 21.03 | -0.16% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,692.00 | 35.90 | 0.41% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |